Lupin's Nagpur Facility Passes USFDA Inspection with VAI Classification

Lupin's Nagpur manufacturing unit received a satisfactory VAI classification from the USFDA, indicating the presence of minor issues that do not warrant regulatory action. The inspection report followed a review conducted in September 2025, and the company remains committed to maintaining high-quality standards.

Drug manufacturer Lupin received a positive assessment from the U.S. Food and Drug Administration (USFDA) for its injectable facility in Nagpur. The facility has been given a Voluntary Action Indicated (VAI) classification after a thorough inspection from September 8 to September 16, 2025.

The VAI status signifies some minor issues, deemed not serious enough to warrant regulatory actions. This outcome comes after a detailed examination of the premises by the regulatory body.

Lupin's Managing Director Nilesh Gupta reaffirmed the company's dedication to superior quality and compliance in their operations. Meanwhile, Lupin's share prices showed a slight increase, trading at Rs 2,109.70 on the BSE.

(With inputs from agencies.)